NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its principal products include UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use; PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and …
Over the last 12 months, insiders at NanoVibronix, Inc. have bought $0 and sold $0 worth of NanoVibronix, Inc. stock.
On average, over the past 5 years, insiders at NanoVibronix, Inc. have bought $32,630 and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 50,000 shares for transaction amount of $12,500 was made by MIKA THOMAS (director) on 2023‑01‑05.
2023-01-05 | director | 50,000 0.1669% | $0.25 | $12,500 | -38.64% | |||
2022-06-15 | 40,000 0.1447% | $0.60 | $23,828 | -43.37% | ||||
2022-06-14 | Chief Financial Officer | 4,000 0.0143% | $0.57 | $2,296 | -41.64% | |||
2022-06-01 | 2,000 0.0071% | $0.69 | $1,380 | -49.71% | ||||
2020-09-29 | director | 10,000 0.1144% | $0.79 | $7,887 | +33.47% | |||
2019-11-20 | director | 25,000 0.2453% | $2.00 | $50,000 | -27.05% |
FASHEK CHRISTOPHER M | 75000 2.6936% | $0.61 | 3 | 0 | <0.0001% | |
MIKA THOMAS | director | 50000 1.7958% | $0.61 | 1 | 0 | <0.0001% |
BROWN STEPHEN RUSSELL | Chief Financial Officer | 4000 0.1437% | $0.61 | 1 | 0 | <0.0001% |
Cassirer Aurora | 2000 0.0718% | $0.61 | 1 | 0 | <0.0001% |